- Home
- Companies
- canada quebec
- solid tumor
Show results for
Refine by
Solid Tumor Suppliers Serving Canada Quebec
56 companies found
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
PRODUCT: C-CAR031. INDICATION: HCC. PLATFORM: CAR-T. PRECLINICAL: GPC3. IIT: -. PHASE 1/1B: -. PHASE 2: -. PARTNERS: ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tulmimetostat is a second-generation EZH2 inhibitor that has been designed to achieve comprehensive target coverage through extended on-target residence time. EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a ...
based inHuntsville, ALABAMA (USA)
Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to ...
Kailos Iota combines TargetRich, our foundational genetic enrichment technology, with next-generation sequencing and statistical machine learning that results in a highly specific cancer assay of multiple solid ...
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator.44 This activation is thought to starve cancer cells of important molecular building blocks, inhibiting tumor cell proliferation, and enhancing antitumor ...
based inEching,, GERMANY
BIOZOL - World of Science distribution service. We provide you more than 25 Million products of more than 260 partner companies around the world. For our customers we overcome national borders, customs and import regulations. So, you receive for ...
contains DAPI nuclear staining dye, fluorescence mounting medium, no background autofluorescence, slowly hardening over weeks, strong reduction of photobleaching, viscous fluid, water-based ...
based inPalo Alto, CALIFORNIA (USA)
Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and ...
Tissue500™ is a comprehensive genomic profiling test that detects clinically relevant mutations in 572 genes to identify a patient’s unique cancer ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based inShanghai, CHINA
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 5 ...
HLX07, recombinant anti-epidermal growth factor receptor (EGFR) humanised monoclonal antibody injection independently researched and developed as biobetter. It was granted IND approvals to be evaluated in clinical trials in China and the United ...
based inGosselies, BELGIUM
We are a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases. OncoDNA is a company specializing in precision for the treatment of cancer and other genetic diseases. We are ...
Oncodeep® is a comprehensive biomarker test designed to guide treatment of advanced, metastatic solid tumors. When your patients are diagnosed with a rare cancer type or an aggressive cancer, when chemotherapy ...
based inChangning District, CHINA
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative ...
based inXiamen, CHINA
Amoy Diagnostics Co., Ltd. (AmoyDx) is an R&D based diagnostic company, focusing on molecular diagnostics for oncology precision medicine. With completely independent intellectual property rights of ADx-ARMS®, Super-ARMS®, ddCapture® and ADx-HANDLE® ...
based inOxford, UNITED KINGDOM
As a leading global provider of diagnostic genomic solutions, our goal is to enable researchers and clinical decision makers to reach the right decisions for each patient, every time. The quality and innovation built into our products for NGS, ...
The HER2 amplification probe consists of a 347kb probe labelled in red, spanning the HER2 (ERBB2) gene and neighbouring regions, and a green probe for the chromosome 17 ...
based inCambridge, MASSACHUSETTS (USA)
Foundation Medicine was founded in 2010 with a mission to bring deep molecular information to the point of care for every patient living with advanced cancer. We’re an essential partner to patients, physicians, researchers, and biopharma ...
Discover tissue AND blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a ...
based inPhiladelphia, PENNSYLVANIA (USA)
With extensive experience optimising processes for analytical, production and R&D laboratories across multiple industries and regulatory environments, we provide consistent, quality informatics solutions. We operate on a truly global basis, serving ...
The Oncomine Clinical Research Grant Program supports investigator-initiated studies (IIS) and education projects, on molecular testing in oncology and reproductive health, with the goal to increase high quality molecular profiling for patients and ...
based inYuseong-gu, SOUTH KOREA
We strive to become a leading biotech company that contributes to human health and well-being by providing innovative therapeutic antibodies to patients with unmet medical needs. We have been committed to developing novel antibody therapeutics since ...
PMC-403 is a monoclonal antibody that targets the human TIE2 that regulate the angiogenesis and vessel maturation in endothelial cells. It binds to TIE2 expressing endothelial cells and normalize VEGF-induced pathological leaky blood vessels in eyes ...
based inBedminster, NEW JERSEY (USA)
Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...